SOURCE: Active Biotech

August 06, 2008 02:36 ET

Active Biotech AB Interim Report January-June 2008

LUND, SWEDEN--(Marketwire - August 6, 2008) -


* Laquinimod - enrolment for the Allegro and Bravo Phase III studies
  proceeding
* ANYARA - Phase III study proceeding
  - Promising median survival from Phase I study
* TASQ - Phase II studies for treatment of prostate cancer in
  progress
* 57-57 - Phase Ib study against SLE successfully concluded
* RhuDex® - Phase IIa study against RA presented positive findings
* Tomas Leanderson new CEO from September 1
* Net sales SEK 5.8 M (5.8)
* Operating result SEK -104.7 M (-108.5)
* Result after tax SEK -99.3 M (-112.1)
* Result per share for the period amounted to SEK -2.07 (-2.46)

Comments from President & CEO Sven Andréasson:

"Enrolment for another clinical Phase III study for laquinimod started during the period and complete Phase II data was published in the respected medical journal The Lancet. The planned interim analysis from the first part of the Phase II/III trial for the ANYARA cancer project presented positive data and the pivotal Phase III study commenced in May. We now have two Phase III projects and three clinical Phase II projects. Consequently, we have further strengthened Active Biotech's position as a company with a balanced and mature project portfolio."

For further information, please contact:
Sven Andréasson
President & CEO
Tel: +46 (0)46-19 20 49

Göran Forsberg
VP Communication & Business Development
Tel: +46 (0)46-19 11 54

Hans Kolam                        Active Biotech AB
CFO                               (Corp. Reg. No. 556223-9227)
Tel +46 (0)46-19 20 44            PO Box 724, SE-220 07 Lund
                                  Tel +46 (0)46-19 20 00
                                  Fax +46 (0)46-19 20 50

This report is also available at www.activebiotech.com


Active Biotech AB Interim Report Jan-June 2008: http://hugin.info/1002/R/1241001/266339.pdf




Copyright © Hugin AS 2008. All rights reserved.

Contact Information